MediGene AG: Medigene Announces Formal Closing Of Capital Measure
Martinsried/Munich, 6 July 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announced today that the capital measure for the funding of its cancer immunotherapy programmes resolved on 12 June 2015 and completed on 30 June 2015 has been formally closed.
Following the entry of the share capital increase from EUR 14,051,815.00 by EUR 5,594,178.00 to EUR 19,645,993.00 in the commercial register on 3 July 2015, the 5,594,178 new shares were admitted to trading on the Regulated Market (Prime Standard) by the Frankfurt Stock Exchange on 3 July 2015. The new shares can be traded with separate ISIN DE000A161NA3, securities identification number WKN A161NA and stock exchange symbol MDGJ from 7 July up to 13 August 2015. From 14 August 2015 on, the new shares will have the same ISIN, securities identification number (WKN), and stock exchange symbol as the existing Medigene shares (ISIN: DE000A1X3W00, WKN: A1X3W0, MDG1).
Baader Bank AG acted as sole global coordinator and sole bookrunner. Trout Capital LLC acted as the US selling agent.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Note: These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction. The shares (the "Shares") of Medigene AG (the "Company") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the Company in the United States.
This publication constitutes neither an offer to sell nor a solicitation to buy securities. The offer will be made solely by means of, and on the basis of, a securities prospectus which has been published. The securities prospectus is available free of charge from Medigene AG, Lochhamer Strasse 11, 82152 Planegg/Martinsried, Germany, as well as on the Medigene AG website under www.medigene.com.
Help employers find you! Check out all the jobs and post your resume.
Following the entry of the share capital increase from EUR 14,051,815.00 by EUR 5,594,178.00 to EUR 19,645,993.00 in the commercial register on 3 July 2015, the 5,594,178 new shares were admitted to trading on the Regulated Market (Prime Standard) by the Frankfurt Stock Exchange on 3 July 2015. The new shares can be traded with separate ISIN DE000A161NA3, securities identification number WKN A161NA and stock exchange symbol MDGJ from 7 July up to 13 August 2015. From 14 August 2015 on, the new shares will have the same ISIN, securities identification number (WKN), and stock exchange symbol as the existing Medigene shares (ISIN: DE000A1X3W00, WKN: A1X3W0, MDG1).
Baader Bank AG acted as sole global coordinator and sole bookrunner. Trout Capital LLC acted as the US selling agent.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Note: These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction. The shares (the "Shares") of Medigene AG (the "Company") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the Company in the United States.
This publication constitutes neither an offer to sell nor a solicitation to buy securities. The offer will be made solely by means of, and on the basis of, a securities prospectus which has been published. The securities prospectus is available free of charge from Medigene AG, Lochhamer Strasse 11, 82152 Planegg/Martinsried, Germany, as well as on the Medigene AG website under www.medigene.com.
Help employers find you! Check out all the jobs and post your resume.